AlloVir (ALVR)

• Market cap: $46.7M
• 1 day: -10.22%
• 5 days: -10.22%
• 1 month: -29.14%
• 3 months: -47.22%
• 6 months: -45.34%
• Year to date: -41.30%
• 1 year: -81.80%
• 5 years: -98.41%
• 10 years: -98.41%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

Employees: 112

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

7% more capital invested

Capital invested by funds: $33.9M [Q2] → $36.3M (+$2.36M) [Q3]

1.89% less ownership

Funds ownership: 40.78% [Q2] → 38.89% (-1.89%) [Q3]

18% less funds holding

Funds holding: 73 [Q2] → 60 (-13) [Q3]

81% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 16

83% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 30